-
1
-
-
71249140249
-
Biologies in the treatment of rheumatoid arthritis and ankylosing spondylitis
-
BRAUN J, KALDEN JR: Biologies in the treatment of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009; 27 (Suppl.55):S 164-7.
-
(2009)
Clin Exp Rheumatol
, vol.27
, Issue.SUPPL.55
, pp. 164-167
-
-
Braun, J.1
Kalden, J.R.2
-
2
-
-
79955844276
-
For the assessment of SpondyloArthritis international society 2010 update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis
-
VAN DER HEIJDE D, SIEPER J, MAKSYMOWYCH WP et al:. for the Assessment of SpondyloArthritis international Society. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011; 70: 905-8.
-
(2011)
Ann Rheum Dis
, vol.70
, pp. 905-908
-
-
Van Der Heijde, D.1
Sieper, J.2
Maksymowych, W.P.3
-
3
-
-
79955826864
-
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
-
BRAUN J, VAN DEN BERG R, BARALIAKOS X et al:. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011; 70: 896-904.
-
(2011)
Ann Rheum Dis
, vol.70
, pp. 896-904
-
-
Braun, J.1
Van Den Berg, R.2
Baraliakos, X.3
-
4
-
-
38549176118
-
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
-
TRACEY D, KLARESKOG L, SASSO EH, SALFELD JG, TAK PP: Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol Ther 2008; 117: 244-79.
-
(2008)
Pharmacol Ther
, vol.117
, pp. 244-279
-
-
Tracey, D.1
Klareskog, L.2
Sasso, E.H.3
Salfeld, J.G.4
Tak, P.P.5
-
5
-
-
37849052961
-
TNFa blockade in human diseases: Mechanisms and future directions
-
WONG M, ZIRING D, KORIN Y et al.: TNFa blockade in human diseases: Mechanisms and future directions. Clin Immunol 2008; 126: 121-36.
-
(2008)
Clin Immunol
, vol.126
, pp. 121-136
-
-
Wong, M.1
Ziring, D.2
Korin, Y.3
-
6
-
-
0035894504
-
Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore
-
DOI 10.1006/abio.2001.5380
-
SANTORA LC, KAYMAKCALAN Z, SAKORAFAS P, KRULL IS, GRANT K: Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore. Anal Biochem 2001; 299: 119-29. (Pubitemid 34053400)
-
(2001)
Analytical Biochemistry
, vol.299
, Issue.2
, pp. 119-129
-
-
Santora, L.C.1
Kaymakcalan, Z.2
Sakorafas, P.3
Krull, I.S.4
Grant, K.5
-
7
-
-
0036229932
-
Binding and functional comparisons of two types of tumor necrosis factor antagonists
-
DOI 10.1124/jpet.301.2.418
-
SCALLON B, CAI A, SOLOWSKI N et al:. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002; 301: 418-26. (Pubitemid 34429950)
-
(2002)
Journal of Pharmacology and Experimental Therapeutics
, vol.301
, Issue.2
, pp. 418-426
-
-
Scallon, B.1
Cai, A.2
Solowski, N.3
Rosenberg, A.4
Song, X.-Y.5
Shealy, D.6
Wagner, C.7
-
8
-
-
36349029627
-
Etanercept: A review of its use in the management of ankylosing spondylitis and psoriatic arthritis
-
HOY SM, SCOTT U: Etanercept. A review of its use in the management of ankylosing spondylitis and psoriatic arthritis. Drugs 2007; 67: 2609-33. (Pubitemid 350159169)
-
(2007)
Drugs
, vol.67
, Issue.17
, pp. 2609-2633
-
-
Hoy, S.M.1
Scott, L.J.2
-
9
-
-
0034888069
-
Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis
-
DOI 10.1002/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F
-
ANDERSON JJ, BARON G, VAN DER HEIJDE D, FELSON DT, DOUGADOS M: Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001; 44: 1876-86. (Pubitemid 32758236)
-
(2001)
Arthritis and Rheumatism
, vol.44
, Issue.8
, pp. 1876-1886
-
-
Anderson, J.J.1
Baron, G.2
Van Der Heijde, D.3
Felson, D.T.4
Dougados, M.5
-
10
-
-
0028575453
-
A new approach to defining disease status in ankylosing spondylitis: The bath ankylosing spondilytis disease activity index
-
GARRETT S, JENKINSON T, KENNEDY LG, WHITELOCK H, GAISFORD P, CALIN A: A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondilytis Disease Activity Index. J Rheumatol 1994; 21: 2286-91.
-
(1994)
J Rheumatol
, vol.21
, pp. 2286-2291
-
-
Garrett, S.1
Jenkinson, T.2
Kennedy, L.G.3
Whitelock, H.4
Gaisford, P.5
Calin, A.6
-
11
-
-
0028129277
-
Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS metrology index
-
JENKINSON TR, MALLORIE PA,WHITELOCK H, KENNEDY LG, GARRETT S, CALIN A: Defining spinal mobility in ankylosing spondylitis (AS): the Bath AS Metrology Index. J Rheumatol 1994; 21: 1694-8. (Pubitemid 24285485)
-
(1994)
Journal of Rheumatology
, vol.21
, Issue.9
, pp. 1694-1698
-
-
Jenkinson, T.R.1
Mallorie, P.A.2
Whitelock, H.C.3
Kennedy, L.G.4
Garrett, S.L.5
Calin, A.6
-
12
-
-
0028579768
-
A new approach to defining functional ability in ankylosing spondylitis: The development of the bath ankylosing spondylitis functional index
-
CALIN A, GARRETT S, WHITELOCK H et al:. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21: 2281-5 .
-
(1994)
J Rheumatol
, vol.21
, pp. 2281-2285
-
-
Calin, A.1
Garrett, S.2
Whitelock, H.3
-
13
-
-
0037007683
-
Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor a
-
DOI 10.1056/NEJMoa012664
-
GORMAN JD, SACK KE, DAVIS JC: Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor a. A' Engl J Med 2002; 346: 1349-56. (Pubitemid 34754607)
-
(2002)
New England Journal of Medicine
, vol.346
, Issue.18
, pp. 1349-1356
-
-
Gorman, J.D.1
Sack, K.E.2
Davis Jr., J.C.3
-
14
-
-
1842628884
-
Results from an open-label extension study of etanercept in ankylosing spondylitis [3]
-
DAVIS JC, WEBB A, LUND S, SACK K: Results from an open-label extension study of etanercept in ankylosing spondylitis. Arthritis Rheum 2004; 52: 302-4. (Pubitemid 38468720)
-
(2004)
Arthritis Care and Research
, vol.51
, Issue.2
, pp. 302-304
-
-
Davis Jr., J.1
Webb, A.2
Lund, S.3
Sack, K.4
-
15
-
-
0037783485
-
Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis
-
DOI 10.1002/art.11017
-
BRANDT J.KHARIOUZOV A.LISTING J et al.: Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003; 48: 1667-75. (Pubitemid 36682375)
-
(2003)
Arthritis and Rheumatism
, vol.48
, Issue.6
, pp. 1667-1675
-
-
Brandt, J.1
Khariouzov, A.2
Listing, J.3
Haibel, H.4
Sorensen, H.5
Grassnickel, L.6
Rudwaleit, M.7
Sieper, J.8
Braun, J.9
-
16
-
-
0242411795
-
Recombinant Human Tumor Necrosis Factor Receptor (Etanercept) for Treating Ankylosing Spondylitis: A Randomized, Controlled Trial
-
DOI 10.1002/art.11325
-
DAVIS JC, VAN DER HEIJDE D, BRAUN J et al:. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis. Arthritis Rheum 2003; 48: 3230-6. (Pubitemid 37409337)
-
(2003)
Arthritis and Rheumatism
, vol.48
, Issue.11
, pp. 3230-3236
-
-
Davis Jr., J.C.1
Van Der Heijde, D.2
Braun, J.3
Dougados, M.4
Cush, J.5
Clegg, D.O.6
Kivitz, A.7
Fleischmann, R.8
Inman, R.9
Tsuji, W.10
-
17
-
-
23644459274
-
Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks
-
DOI 10.1136/ard.2004.035105
-
DAVIS JC, VAN DER HEIJDE D, BRAUN J et al:. Sustained durability and tolerability of etanercept in ankylosing spondylitis. Ann Rheum Dis 2005; 64: 1557-62. (Pubitemid 41532037)
-
(2005)
Annals of the Rheumatic Diseases
, vol.64
, Issue.11
, pp. 1557-1562
-
-
Davis, J.C.1
Van Der Heijde, D.M.2
Braun, J.3
Dougados, M.4
Cush, J.5
Clegg, D.6
Inman, R.D.7
Kivitz, A.8
Zhou, L.9
Solinger, A.10
Tsuji, W.11
-
18
-
-
39549118012
-
Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis
-
DOI 10.1136/ard.2007.078139
-
DAVIS JC, VAN DER HEIJDE D, BRAUN J et al:. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 2008; 67: 346-52. (Pubitemid 351281269)
-
(2008)
Annals of the Rheumatic Diseases
, vol.67
, Issue.3
, pp. 346-352
-
-
Davis Jr., J.C.1
Van Der Heijde, D.M.2
Braun, J.3
Dougados, M.4
Clegg, D.O.5
Kivitz, A.J.6
Fleischmann, R.M.7
Inman, R.D.8
Ni, L.9
Lin, S.-L.10
Tsuji, W.H.11
-
19
-
-
9644266805
-
Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis
-
DOI 10.1136/ard.2004.020875
-
CALIN A, DIJKMANS BAC, EMERY P et al:. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004; 63: 1594-600. (Pubitemid 39573687)
-
(2004)
Annals of the Rheumatic Diseases
, vol.63
, Issue.12
, pp. 1594-1600
-
-
Calin, A.1
Dijkmans, B.A.C.2
Emery, P.3
Hakala, M.4
Kalden, J.5
Leirisalo-Repo, M.6
Mola, E.M.7
Salvarani, C.8
Sanmarti, R.9
Sany, J.10
Sibilia, J.11
Sieper, J.12
Van Der Linden, S.13
Veys, E.14
Appel, A.M.15
Fatenejad, S.16
-
20
-
-
67149115523
-
Etanercept in the longterm treatment of patients with ankylosing spondylitis
-
DIJKMANS BAC, EMERY P, HAKALA M et al:. Etanercept in the longterm treatment of patients with ankylosing spondylitis. J Rheumatol 2009;36: 1256-64.
-
(2009)
J Rheumatol
, vol.36
, pp. 1256-1264
-
-
Dijkmans, B.A.C.1
Emery, P.2
Hakala, M.3
-
21
-
-
73449140249
-
Assessment of clinical efficacy in a randomized, double-blind study of etanercept and sulphasalazine in patients with ankylosing spondylitis
-
BRAUN J, HUANG F, BURGOS-VARGAS R et al:. Assessment of clinical efficacy in a randomized, double-blind study of etanercept and sulphasalazine in patients with ankylosing spondylitis. Arthritis Rheum 2008; 58: S415.
-
(2008)
Arthritis Rheum
, vol.58
-
-
Braun, J.1
Huang, F.2
Burgos-Vargas, R.3
-
22
-
-
76649091242
-
Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA
-
PAVELKA K, FOREJTOVA S, STOLFA J et al:. Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA, Clin Exp Rheumatol 2009; 27: 958-63.
-
(2009)
Clin Exp Rheumatol
, vol.27
, pp. 958-963
-
-
Pavelka, K.1
Forejtova, S.2
Stolfa, J.3
-
23
-
-
1042290332
-
Once-Weekly Administration of 50 mg Etanercept in Patients with Active Rheumatoid Arthritis: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
-
DOI 10.1002/art.20019
-
KEYSTONE EC, SCHIFF MH, KREMER JM et al:. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results ofamulticenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004; 50: 353-63. (Pubitemid 38198818)
-
(2004)
Arthritis and Rheumatism
, vol.50
, Issue.2
, pp. 353-363
-
-
Keystone, E.C.1
Schiff, M.H.2
Kremer, J.M.3
Kafka, S.4
Lovy, M.5
De Vries, T.6
Burge, D.J.7
-
24
-
-
33751302864
-
Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis
-
DOI 10.1136/ard.2006.056747
-
VAN DER HEIJDE D, DA SILVA JC, DOUGADOS M et al:. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis 2006; 65: 1572-7. (Pubitemid 44799667)
-
(2006)
Annals of the Rheumatic Diseases
, vol.65
, Issue.12
, pp. 1572-1577
-
-
Van Der Heijde, D.1
Da Silva, J.C.2
Dougados, M.3
Geher, P.4
Van Der Horst-Bruinsma, I.5
Juanola, X.6
Olivieri, I.7
Raeman, F.8
Settas, L.9
Sieper, J.10
Szechinski, J.11
Walker, D.12
Boussuge, M.-P.13
Wajdula, J.S.14
Paolozzi, L.15
Fatenejad, S.16
-
25
-
-
34447302822
-
Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly
-
DOI 10.1093/rheumatology/kem069
-
BRAUN J, MCHUGH N, SINGH A, WAJDULA JS, SATO R: Improvement in patient-reported outcomes from patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. Rheumatology (Oxford) 2007; 46: 999-1004. (Pubitemid 47062511)
-
(2007)
Rheumatology
, vol.46
, Issue.6
, pp. 999-1004
-
-
Braun, J.1
McHugh, N.2
Singh, A.3
Wajdula, J.S.4
Sato, R.5
-
26
-
-
14944366460
-
Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis
-
DOI 10.1093/rheumatology/keh475
-
BRANDT J,LISTING J,HAlBEL H et al:. Longterm efficacy and safety of etanercept after readministration in patients with ankylosing spondylitis. Rheumatology (Oxford) 2005; 44: 342-8. (Pubitemid 40361291)
-
(2005)
Rheumatology
, vol.44
, Issue.3
, pp. 342-348
-
-
Brandt, J.1
Listing, J.2
Haibel, H.3
Sorensen, H.4
Schwebig, A.5
Rudwaleit, M.6
Sieper, J.7
Braun, J.8
-
27
-
-
79952109388
-
Extended dosing of etanercept 25 mg can be effective in patients with ankylosing spondylitis: A retrospective analysis
-
LEE J, NOH JW, HWANG JW et al:. Extended dosing of etanercept 25 mg can be effective in patients with ankylosing spondylitis: a retrospective analysis. Clin Rheumatol 2010; 29: 1149-54.
-
(2010)
Clin Rheumatol
, vol.29
, pp. 1149-1154
-
-
Lee, J.1
Noh, J.W.2
Hwang, J.W.3
-
28
-
-
83455250623
-
Computed tomography guided intra-articular injection of etanercept in the sacroiliac joint is an effective mode of treatment of ankylosing spondylitis
-
CUI Y, XIAO Z, SHUXIA W et al:. Computed tomography guided intra-articular injection of etanercept in the sacroiliac joint is an effective mode of treatment of ankylosing spondylitis. Scand J Rheumatol 2009; 27: 958-63.
-
(2009)
Scand J Rheumatol
, vol.27
, pp. 958-963
-
-
Cui, Y.1
Xiao, Z.2
Shuxia, W.3
-
29
-
-
17244374728
-
Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept
-
DOI 10.1002/art.20977
-
BARALIAKOS X, DAVIS J, TSUJI W, BRAUN J: Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis Rheum 2005; 52: 1216-23. (Pubitemid 40530129)
-
(2005)
Arthritis and Rheumatism
, vol.52
, Issue.4
, pp. 1216-1223
-
-
Baraliakos, X.1
Davis, J.2
Tsuji, W.3
Braun, J.4
-
30
-
-
23944517016
-
Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept
-
DOI 10.1136/ard.2004.032441
-
RUDWALEIT M, BARALIAKOS X, LISTING J, BRANDT J, SIEPER J, BRAUN J: Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept. Ann Rheum Dis 2005; 64: 1305-10. (Pubitemid 41206247)
-
(2005)
Annals of the Rheumatic Diseases
, vol.64
, Issue.9
, pp. 1305-1310
-
-
Rudwaleit, M.1
Baraliakos, X.2
Listing, J.3
Brandt, J.4
Sieper, J.5
Braun, J.6
-
31
-
-
43949140512
-
Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept
-
DOI 10.1002/art.23471
-
VAN DER HEIJDE D, LANDEWE R, EINSTEIN S, ORY P et al:. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008; 58: 1324-31. (Pubitemid 351705922)
-
(2008)
Arthritis and Rheumatism
, vol.58
, Issue.5
, pp. 1324-1331
-
-
Van Der Heijde, D.1
Landewe, R.2
Einstein, S.3
Ory, P.4
Vosse, D.5
Ni, L.6
Lin, S.-L.7
Tsuji, W.8
Davis Jr., J.C.9
-
32
-
-
24644446382
-
Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy
-
DOI 10.1002/art.21330
-
DAVIS JC, VAN DER HEIJDE D, DOUGADOS M, WOOLLEY JM: Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy. Arthritis Rheum 2005; 53: 494-501. (Pubitemid 41278913)
-
(2005)
Arthritis Care and Research
, vol.53
, Issue.4
, pp. 494-501
-
-
Davis, J.C.1
Van Der Heijde, D.2
Dougados, M.3
Woolley, J.M.4
-
33
-
-
41849104176
-
Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept
-
BOONEN A, PATEL V, TRAINA S, CHIOU CF, MAETZEL A, TSUJI W: Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept. J Rheumatol 2008; 35: 662-7.
-
(2008)
J Rheumatol
, vol.35
, pp. 662-627
-
-
Boonen, A.1
Patel, V.2
Traina, S.3
Chiou, C.F.4
Maetzel, A.5
Tsuji, W.6
-
34
-
-
78149489356
-
Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis
-
BARKHAM N, COATES LC, KEEN H et al:. Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis. Ann Rheum Dis 2010; 69: 1926-8
-
(2010)
Ann Rheum Dis
, vol.69
, pp. 1926-1928
-
-
Barkham, N.1
Coates, L.C.2
Keen, H.3
-
35
-
-
0034729950
-
Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial
-
MEASE PJ, GOFFE BS, METZ J, VANDERSTOEP A, FINCK B, BURGE DJ: Etanercept in the treatment of psoriatic arthritis and psoriasis; a randomised trial. Lancet 2000; 356: 385-90. (Pubitemid 30487495)
-
(2000)
Lancet
, vol.356
, Issue.9227
, pp. 385-390
-
-
Mease, P.J.1
Goffe, B.S.2
Metz, J.3
Vanderstoep, A.4
Finck, B.5
Burge, D.J.6
-
36
-
-
3042649266
-
Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression
-
DOI 10.1002/art.20335
-
MEASE PJ, KIVITZ AJ, BURCH FX et al:. Etanercept treatment of psoriatic arthritis. Safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50: 2264-72. (Pubitemid 38924405)
-
(2004)
Arthritis and Rheumatism
, vol.50
, Issue.7
, pp. 2264-2272
-
-
Mease, P.J.1
Kivitz, A.J.2
Burch, F.X.3
Siegel, E.L.4
Cohen, S.B.5
Ory, P.6
Salonen, D.7
Rubenstein, J.8
Sharp, J.T.9
Tsuji, W.10
-
37
-
-
33644861049
-
Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: A 26-week observational study
-
DOI 10.1093/rheumatology/kei153
-
DE VLAM K, LORIES RJU: Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study. Rheumatology (Oxford) 2006;46:321-4. (Pubitemid 43372848)
-
(2006)
Rheumatology
, vol.45
, Issue.3
, pp. 321-324
-
-
De Vlam, K.1
Lories, R.J.U.2
-
38
-
-
33645804643
-
Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept
-
MEASE PJ, KIVITZ AJ, BURCH FX et al:. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006; 33: 712-21.
-
(2006)
J Rheumatol
, vol.33
, pp. 712-721
-
-
Mease, P.J.1
Kivitz, A.J.2
Burch, F.X.3
-
39
-
-
34147219117
-
Survival on TNF antagonists in spondyloarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER
-
On BEHALF OF THE BIOBADASER GROUP
-
CARMONA L, REINO-GOMEZ JJ ON BEHALF OF THE BIOBADASER GROUP: Survival on TNF antagonists in spondyloarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther 2006; 8: R72.
-
(2006)
Arthritis Res Ther
, vol.8
-
-
Carmona, L.1
Reino-Gomez, J.J.2
-
41
-
-
54349107274
-
Life-table analysis of etanercept with or without methotrexate in patients with psoriatic arthritis
-
SPADARO A, CECCARELLI F, SCRIVO R, VALESINIG G: Life-table analysis of etanercept with or without methotrexate in patients with psoriatic arthritis. Ann Rheum Dis 2008; 67: 1650-1.
-
(2008)
Ann Rheum Dis
, vol.67
, pp. 1650-1651
-
-
Spadaro, A.1
Ceccarelli, F.2
Scrivo, R.3
Valesinig, G.4
-
42
-
-
65449189497
-
Persistence with anti-tumour necrosis factortherapies in patients with psoriatic arthritis: Observational study from the British Society of rheumatology biologies register
-
SAAD AA, ASHCROFT DM, WATSON KD, HYRICH KL, NOYCE PR, SYMMONS DPM: Persistence with anti-tumour necrosis factortherapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologies Register. Arthritis Res Ther 2009,11:R52
-
(2009)
Arthritis Res Ther
, vol.11
-
-
Saad, A.A.1
Ashcroft, D.M.2
Watson, K.D.3
Hyrich, K.L.4
Noyce, P.R.5
Symmons, D.P.M.6
-
43
-
-
83455176384
-
Etanercept benefits skin, joints, and entheseal symptoms in patients with psoriasis and psoriatic arthritis, the PRESTA trial
-
KIRKHAM BW, STERRY W, ORMEROD A et al:. Etanercept benefits skin, joints, and entheseal symptoms in patients with psoriasis and psoriatic arthritis, the PRESTA trial. Arthritis Rheum 2009; 60 (Suppl. 10): S194
-
(2009)
Arthritis Rheum
, vol.60
, Issue.SUPPL. 10
-
-
Kirkham, B.W.1
Sterry, W.2
Ormerod, A.3
-
44
-
-
72449210551
-
Long-term experience with etanercept in psoriatic arthritis patients: A 3-year observational study
-
MAZZOTTA A, ESPOSITO M, SCHIPANI C, CHIMENTI S: Long-term experience with etanercept in psoriatic arthritis patients: a 3-year observational study. J Dermatolog Treat 2009; 20: 354-8.
-
(2009)
J Dermatolog Treat
, vol.20
, pp. 354-358
-
-
Mazzotta, A.1
Esposito, M.2
Schipani, C.3
Chimenti, S.4
-
45
-
-
77953181751
-
Patients reported outcomes in a randomized trial of etanercept in psoriatic arthritis
-
MEASE PJ, WOOLEY JM, SINGH A, TSUJI W, DUNN M, CHOIU CF: Patients reported outcomes in a randomized trial of etanercept in psoriatic arthritis. J Rheumatol 2010; 37: 1221-7.
-
(2010)
J Rheumatol
, vol.37
, pp. 1221-1227
-
-
Mease, P.J.1
Wooley, J.M.2
Singh, A.3
Tsuji, W.4
Dunn, M.5
Choiu, C.F.6
-
46
-
-
79955669942
-
The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept
-
LUBRANO E, SPADARO A, MARCHESONI A et al:. The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept. Clin Exp Rheumatol 2011; 29: 80-4.
-
(2011)
Clin Exp Rheumatol
, vol.29
, pp. 80-84
-
-
Lubrano, E.1
Spadaro, A.2
Marchesoni, A.3
-
48
-
-
0035459313
-
Efficacy of Etanercept in the Treatment of the Entheseal Pathology in Resistant Spondylarthropathy: A Clinical and Magnetic Resonance Imaging Study
-
DOI 10.1002/1529-0131(200109)44:9<2112::AID-ART363>3.0.CO;2-H
-
MARZO-ORTEGA H, MCGONAGLE D, OXONNOR P, EMERY P: Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum 2001; 44: 2112-7. (Pubitemid 33644055)
-
(2001)
Arthritis and Rheumatism
, vol.44
, Issue.9
, pp. 2112-2117
-
-
Marzo-Ortega, H.1
McGonagle, D.2
O'Connor, P.3
Emery, P.4
-
49
-
-
1542515178
-
Successful Short Term Treatment of Patients with Severe Undifferentiated Spondyloarthritis with the Anti-Tumor Necrosis Factor-alpha Fusion Receptor Protein Etanercept
-
BRANDT J,KHARIOUZOV A,LISTING J et al.: Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept. J Rheumatol 2004; 31: 531-8. (Pubitemid 38337615)
-
(2004)
Journal of Rheumatology
, vol.31
, Issue.3
, pp. 531-538
-
-
Brandt, J.1
Khariouzov, A.2
Listing, J.3
Haibel, H.4
Sorensen, H.5
Rudwaleit, M.6
Sieper, J.7
Braun, J.8
-
50
-
-
24644509214
-
Decreased pain and synovial inflammation after etanercept therapy in patients with reactive and undifferentiated arthritis: An open-label trial
-
DOI 10.1002/art.21323
-
FLAGG SD, MEADOR R, HSIA E, KITUMNUAYPONG T, SCHUMACHER HR JR.: Decreased pain and synovial inflammation after etanercept therapy in patients with reactive and undifferentiated arthritis: an open-label trial. Arthritis Rheum 2005; 53: 613-7. (Pubitemid 41278928)
-
(2005)
Arthritis Care and Research
, vol.53
, Issue.4
, pp. 613-617
-
-
Flagg, S.D.1
Meador, R.2
Hsia, E.3
Kitumnuaypong, T.4
Schumacher Jr., H.R.5
-
51
-
-
37349120419
-
Switching tumor necrosis factor a inhibitors in HLA-B27-associated severe heel enthesitis
-
DOI 10.1002/art.23096
-
OLIVIERI I, SCARANO E, PADULA A, D'ANGELO S, CANTINI F: Switching tumor necrosis factor a inhibithors in HLA-B27-associated severe heel enthesitis. Arthritis Rheum 2007; 57: 1572-4. (Pubitemid 350308861)
-
(2007)
Arthritis Care and Research
, vol.57
, Issue.8
, pp. 1572-1574
-
-
Olivieri, I.1
Scarano, E.2
Padula, A.3
D'Angelo, S.4
Cantini, F.5
-
52
-
-
77955445434
-
A randomised, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloathritis: The HEEL trial
-
DOUGADOS M, COMBE B. BRAUN J et al:. A randomised, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloathritis: the HEEL trial. Ann Rheum Dis 2010; 69: 1430-5.
-
(2010)
Ann Rheum Dis
, vol.69
, pp. 1430-1435
-
-
Dougados, M.1
Combe, B.2
Braun, J.3
-
53
-
-
0030738875
-
The outcome of ankylosing spondylitis: A study of 100 patients
-
GRAN JT, SKOMSVOLL JF: The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol 1997; 36: 766-71.
-
(1997)
Br J Rheumatol
, vol.36
, pp. 766-771
-
-
Gran, J.T.1
Skomsvoll, J.F.2
-
54
-
-
46849108338
-
Prevalence and characteristics of uveitis in the spondyloarthropathies: A systematic literature review
-
ZEBOULON N, DOUGADOS M, GOSSEC L: Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis 2008; 67: 955-9.
-
(2008)
Ann Rheum Dis
, vol.67
, pp. 955-359
-
-
Zeboulon, N.1
Dougados, M.2
Gossec, L.3
-
55
-
-
0029097323
-
HLA-B27 and spondyloarthropathy: Value for early diagnosis?
-
GRAN JT, HUSBY G: HLA-B27 and spondyloarthropathy: value for early diagnosis? J Med Genet 1995; 32: 497-501.
-
(1995)
J Med Genet
, vol.32
, pp. 497-501
-
-
Gran, J.T.1
Husby, G.2
-
56
-
-
8444244864
-
Effect of etanercept on iritis in patients with ankylosing spondylitis [5]
-
DOI 10.1002/art.20754
-
ROSENBAUM JT: Effect of etanercept on iritis in patients with ankylosing spondylitis [letter]. Arthritis Rheum 2004; 50: 3736-7. (Pubitemid 39488709)
-
(2004)
Arthritis and Rheumatism
, vol.50
, Issue.11
, pp. 3736-3737
-
-
Rosenbaum, J.T.1
-
57
-
-
0034980872
-
Methotrexate therapy for chronic noninfectious uveitis: Analysis of a case series of 160 patients
-
DOI 10.1016/S0161-6420(01)00576-0, PII S0161642001005760
-
SAMSON CM, WAHEED N, BALTATZIS S, FOSTER CS: Methotrexate therapy for chronic noninfectious uveitis: an analysis of a case series of 160 patients. Ophthalmology 2001; 108: 1134-9. (Pubitemid 32500033)
-
(2001)
Ophthalmology
, vol.108
, Issue.6
, pp. 1134-1139
-
-
Samson C.Michael1
Waheed, N.2
Baltatzis, S.3
Foster C.Stephen4
-
58
-
-
23644452510
-
Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept
-
DOI 10.1002/art.21197
-
BRAUN J.BARALIAKOS X,LISTING J.SIEPER J: Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005;52:2447-51. (Pubitemid 41117431)
-
(2005)
Arthritis and Rheumatism
, vol.52
, Issue.8
, pp. 2447-2451
-
-
Braun, J.1
Baraliakos, X.2
Listing, J.3
Sieper, J.4
-
59
-
-
73449114984
-
Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials
-
SIEPER J, KOENIG AS, BAUMGARTNER S et al:. Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann Rheum Dis 2010; 69: 226-9.
-
(2010)
Ann Rheum Dis
, vol.69
, pp. 226-229
-
-
Sieper, J.1
Koenig, A.S.2
Baumgartner, S.3
-
60
-
-
42949127087
-
Do TNF-blockers reduce or induce uveitis?
-
DOI 10.1093/rheumatology/ken091
-
COBO-IBANEZ T.DEL CARMEN ORDONEZ M, MUNOZ-FERNANDEZ S, MADERO-PRADO R, MARTIN-MOLA E: Do TNF-blockers reduce or induce uveitis? Rheumatology (Oxford) 2008;47:731-2. (Pubitemid 351619221)
-
(2008)
Rheumatology
, vol.47
, Issue.5
, pp. 731-732
-
-
Cobo-Ibanez, T.1
Del Carmen Ordonez, M.2
Munoz-Fernandez, S.3
Madero-Prado, R.4
Martin-Mola, E.5
-
61
-
-
35348914933
-
Do tumor necrosis factor inhibitors cause uveitis? A registry-based study
-
DOI 10.1002/art.22918
-
LIM LL, FRAUNFELDER FW, ROSENBAUM JT: Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007; 56: 3248-52. (Pubitemid 47585419)
-
(2007)
Arthritis and Rheumatism
, vol.56
, Issue.10
, pp. 3248-3252
-
-
Lim, L.L.1
Fraunfelder, F.W.2
Rosenbaum, J.T.3
-
62
-
-
43949120761
-
Uveitis following the use of tumor necrosis factor α inhibitors: Comment on the article by Lim et al
-
DOI 10.1002/art.23440
-
SCRIVO R, SPADARO A, SPINELLI FR, VALESINI G: Uveitis following the use of tumor necrosis factor α inhibitors: comment on the article by Lim et al. Arthritis Rheum 2008; 58: 1555-6. (Pubitemid 351705951)
-
(2008)
Arthritis and Rheumatism
, vol.58
, Issue.5
, pp. 1555-1556
-
-
Scrivo, R.1
Spadaro, A.2
Spinelli, F.R.3
Valesini, G.4
-
63
-
-
42449150773
-
Uveitis and tumour necrosis factor blockade in ankylosing spondylitis
-
DOI 10.1136/ard.2007.077370
-
COATES LC, MCGONAGLE DG, BENNETT AN, MARZO-ORTEGA M: Uveitis and tumor necrosis factor blockade in ankylosing spondylitis. Ann Rheum Dis 2009; 67: 729-30. (Pubitemid 351571948)
-
(2008)
Annals of the Rheumatic Diseases
, vol.67
, Issue.5
, pp. 729-730
-
-
Coates, L.C.1
McGonagle, D.G.2
Bennett, A.N.3
Emery, P.4
Marzo-Ortega, H.5
-
64
-
-
67650088393
-
Paradoxical adverse events of antitumour necrosis factor therapy for spondyloarthropaties: A retrospective study
-
FOUACHE D, GOEB V, MASSY-GUILLEMANT N et al:. Paradoxical adverse events of antitumour necrosis factor therapy for spondyloarthropaties: a retrospective study. Rheumatology (Oxford) 2009; 48: 761-4.
-
(2009)
Rheumatology (Oxford)
, vol.48
, pp. 761-764
-
-
Fouache, D.1
Goeb, V.2
Massy-Guillemant, N.3
-
65
-
-
37549003226
-
Pathologic alterations of the heart and the kidney in patients with ankylosing spondylitis
-
LANGE U, STAPFER G, DITTING T et al:. Pathologic alterations of the heart and the kidney in patients with ankylosing spondylitis. Eur J Med Res 2007; 14: 573-81.
-
(2007)
Eur J Med Res
, vol.14
, pp. 573-581
-
-
Lange, U.1
Stapfer, G.2
Ditting, T.3
-
67
-
-
28844495656
-
Les manifestations rénales de la spondylarthrite ankylosante: A propos de 210 cas
-
DOI 10.1016/j.revmed.2005.07.017, PII S0248866305003565
-
BEN TAARIT C, AJLANI H, BEN MOUSSA F, BEN ABDALLAH T, BEN MAIZ H, KHEDHER A: Renal involvement in ankylosing spondylitis: concerning 210 cases. Rev Med Interne 2005; 26: 966-9. (Pubitemid 41767500)
-
(2005)
Revue de Medecine Interne
, vol.26
, Issue.12
, pp. 966-969
-
-
Ben Taarit, C.1
Ajlani, H.2
Ben Moussa, F.3
Ben Abdallah, T.4
Ben Maiz, H.5
Khedher, A.6
-
68
-
-
0031675375
-
Renal diseases in ankylosing spondylitis: Review of the literature illustrated by case reports
-
STROBEL ES, FRITSCHKA E: Renal diseases in ankylosing spondylitis: review of the literature illustrated by case reports. Clin Rheumatol 1998; 17: 524-30. (Pubitemid 28566334)
-
(1998)
Clinical Rheumatology
, vol.17
, Issue.6
, pp. 524-530
-
-
Strobel, E.-S.1
Fritschka, E.2
-
69
-
-
36248992938
-
Ankylosing spondylitis-related secondary amyloidosis responded well to etanercept: A report of three patients
-
DOI 10.1007/s10067-007-0679-x
-
KOBAK S, OKSEL F, KABASAKAL Y, DOGANAVSARGIL E: Ankylosing spondylitis-related secondary amyloidosis responded well to etanercept: a report of three patients. Clin Rheumatol 2007; 26: 2191-4. (Pubitemid 350120369)
-
(2007)
Clinical Rheumatology
, vol.26
, Issue.12
, pp. 2191-2194
-
-
Kobak, S.1
Oksel, F.2
Kabasakal, Y.3
Doganavsargil, E.4
-
70
-
-
39549103518
-
Response to anti-TNF-alpha treatment for secondary renal amyloidosis in a patient with ankylosing spondylitis
-
BELLISS1MO S, FERRUCCI MG, GALLO A, STISI S: Response to anti-TNF-alpha treatment for secondary renal amyloidosis in a patient with ankylosing spondylitis. Reumatismo 2007; 59: 240-3.
-
(2007)
Reumatismo
, vol.59
, pp. 240-243
-
-
Bellisslmo, S.1
Ferrucci, M.G.2
Gallo, A.3
Stisi, S.4
|